Trials / Completed
CompletedNCT02069535
An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This trial is an open, national, multi-centre trial. The main objective of this trial is to assess the tolerability of the up-dosing phase of AVANZ® Cupressus arizonica by measurement of related Adverse Events.
Detailed description
The main objective of this trial is to assess the tolerability of the up-dosing phase of AVANZ® Cupressus arizonica, the measurement rate is the frequency of patients with investigational medicinal product (IMP)-related adverse events (AEs) will be the primary endpoint.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AVANZ Cupressus | AVANZ Cupressus |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2014-02-24
- Last updated
- 2015-01-06
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02069535. Inclusion in this directory is not an endorsement.